According to filings with the U.S. Securities and Exchange Commission, Auxergen is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Gregory Contreras played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Auxergen
Engineered biologics for human, plant and environmental health. Auxergen applies novel biocontrol solutions to human, agricultural and environmental disease, to reduce the chemical loading of our soils and waterways. For plant health, we are developing phage-based cures for Xylella Fastidiosa disease in olive, grapes, oleander, etc., and Xanthamonas disease of citrus, rice, bananas, and cruciferous vegetables. In human health, we are proud to introduce, under the brand Jeunase(TM), an irritation-free, botanical skin cream which lifts, tightens, lightens and removes spots, evens tone, improves microcirculation, and radiance. Jeunase(TM) Cell Vitality Cream is available at jeunase.com. Auxergen is a Maryland “Qualified Maryland Biotechnology Company,” so designated by the Maryland Department of Commerce, enabling tax credits to Auxergen investors to promote biotech R&D in Maryland.

To learn more about Auxergen, visit http://www.auxergen.com/

Contact:
Gregory Contreras, Chief Executive Officer
410-336-9877
https://www.linkedin.com/in/gregcontreras/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.